× Close

The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.

Items from 1 to 6 out of 6 results
customise view
items per page:

  • [1] Drews J., Drug discovery: a historical perspective, Science, 2000, 287, 1960-1964

  • [2] Vane J.R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat. New Biol. 1971, 231, 232-235

  • [3. Kauselmann G., Dopazo A., Link W., Identification of diseaserelevant genes for molecularly-targeted drug discovery, Current cancer drug targets, 2012, 12, 1-13

  • [4] Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S., Leszczyniecka M., et al., Validating cancer drug targets, Nature, 2006, 441, 451-456

  • [5] Kola I., Landis J., Can the pharmaceutical industry reduce attrition rates? Nature reviews Drug discovery, 2004, 3, 711-715

  • RELATION NAME